Small Molecule PHD Inhibitors Stabilizing HIF for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by PHD activity, such as ischemic reperfusion injury, inflammatory bowel disease, and respiratory disorders, lack effective small molecule inhibitors that can specifically target and inhibit PHD proteins to stabilize HIF, thereby promoting tissue repair and reducing inflammation.
Innovation Solution
Development of novel small molecule PHD inhibitors with specific structural formulas, such as those described in Formulas (I)-(XXIII), which can inhibit PHD proteins, thereby stabilizing HIF and treating various diseases including ischemic reperfusion injury, inflammatory bowel disease, and respiratory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for diseases mediated by PHD activity, then existing therapeutic options are available, but effective small molecule inhibitors that can specifically target and inhibit PHD proteins are lacking
Solution Approach 1:
The patent segments the broad class of PHD proteins into three distinct isoforms (PHD1, PHD2, and PHD3) with different regulatory roles. The invention provides specific small molecule inhibitors that can selectively target different PHD isoforms, allowing for tailored therapeutic approaches for different diseases. This segmentation enables precise inhibition of specific PHD proteins rather than non-specific inhibition, resolving the contradiction between treatment effectiveness and specificity availability.
Solution Approach 2:
The patent employs parameter changes by developing small molecule inhibitors with specific chemical structures (Formulas I-XXIII) that have optimized binding affinity and selectivity for PHD proteins. By modifying molecular parameters such as chemical groups, stereochemistry, and molecular weight, the invention creates a series of compounds with varying degrees of potency and selectivity, thus providing adaptable therapeutic options for different disease conditions while maintaining high effectiveness.
2Reliability
If PHD proteins are inhibited to stabilize HIF, then tissue repair is promoted and inflammation is reduced, but the complexity of developing specific small molecule inhibitors increases
Solution Approach 1:
The patent develops small molecule inhibitors with a core structural framework (picolinamide derivative) that can universally inhibit multiple PHD isoforms while allowing for modifications to achieve isoform-specific inhibition. This multi-functional approach enables a single compound to potentially treat multiple diseases mediated by different PHD isoforms, reducing the overall complexity of inhibitor development while maintaining the beneficial effects of HIF stabilization for tissue repair and inflammation reduction.
Solution Approach 2:
The invention uses the HIF protein as an intermediary mediator between PHD inhibition and the desired therapeutic outcomes. By designing small molecules that inhibit PHD proteins, the invention indirectly stabilizes HIF, which then mediates the downstream effects of promoting tissue repair and reducing inflammation. This intermediary approach simplifies the drug design process compared to directly targeting multiple downstream pathways, as the small molecules only need to inhibit PHD proteins to achieve the desired therapeutic effects.
Data Source
AI summary
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).